1don MSN
FDA approves cryoablation to treat breast cancer in women over 70 with small, low-risk tumors
The FDA has approved cryoablation — a procedure that freezes and kills small breast tumors without surgery — for women over ...
ORLANDO -- Cryoablation without excision for low-risk, early-stage breast cancer may be an option for women over 60, 5-year follow-up results from the ICE3 trial showed. At a mean follow-up of 54.2 ...
Laparoscopic and percutaneous approaches have similar short-term efficacy in treating renal tumors. Laparoscopic (LAP) and CT-guided percutaneous (PERC) cryoablation for renal tumors result in similar ...
IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...
Percutaneous cryoablation may provide a safe and effective treatment option for patients with renal tumors, new findings suggest. David J. Breen, MD, and colleagues from University Hospitals of ...
The ICE3 study was the largest controlled multicenter clinical trial ever performed for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors. The 5-year recurrence ...
CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...
The ProSense® Cryoablation System could be a game changer for women over 70 with early-stage, low-risk breast cancer. For decades, breast cancer treatment has often meant surgery, which can be an ...
IceCure Medical has received US Food and Drug Administration (FDA) marketing authorisation for its ProSense cryoablation system to treat breast cancer. The FDA's approval requires IceCure to conduct a ...
Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized small renal masses, supporting its role as a surgery-sparing local ...
CAESAREA, Israel, Sept. 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...
PFA was noninferior to cryoablation for first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation. Tissue-selective energy delivery and short application times offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results